Completion of Marketing Authorization Transfer for Myoclonus Treatment "Myocarm® Oral Solution 33.3%"
NQ Score
100/100
AI Summary (NQ-processed)
Cheplapharm K.K. announced the completion of the marketing authorization transfer for the myoclonus treatment "Myocarm® Oral Solution 33.3%" from UCB Japan Co., Ltd., effective April 1, 2026. The sales transfer from Taiho Pharmaceutical Co., Ltd. was also completed on the same date. This brings Cheplapharm's total inherited pharmaceutical products to 15 products across 36 items. The company aims to ensure stable supply and quality maintenance.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What pharmaceutical product did Cheplapharm K.K. inherit?
- A: It inherited the myoclonus treatment "Myocarm® Oral Solution 33.3%."
- Q: How many pharmaceutical products has Cheplapharm K.K. inherited in total?
- A: It has inherited a cumulative total of 15 products across 36 items.